Key Takeaways
- A comprehensive worldwide settlement has resolved all patent litigation between BioMarin and Ascendis Pharma concerning Yuviwel.
- BioMarin secures a 20% royalty on Yuviwel’s U.S. net revenue and 18% on sales across the EU, Brazil, and South Korea.
- The royalty structure applies retroactively from Yuviwel’s initial commercial launch and extends through May 2030.
- The licensing agreement encompasses all existing and future indications for Yuviwel, including treatments for achondroplasia and hypochondroplasia.
- BioMarin agrees to withdraw its ITC Section 337 complaint and terminate ongoing litigation in several international jurisdictions.
On August 30, 2026, BioMarin Pharmaceutical (BMRN) finalized a comprehensive patent agreement with Ascendis Pharma, bringing closure to contentious intellectual property disputes surrounding CNP technology utilized in Ascendis’s therapeutic product Yuviwel. At the time of the settlement announcement, BMRN stock experienced a decline of 0.96%.
BioMarin Pharmaceutical Inc., BMRN
The pharmaceutical rivals had been engaged in legal confrontations spanning numerous international venues, including formal proceedings at the U.S. International Trade Commission. This comprehensive settlement consolidates all outstanding matters into a single binding agreement.
According to the settlement terms, Ascendis has committed to compensating BioMarin with a 20% royalty calculated from Yuviwel’s net sales within the United States, with payments dating back to the medication’s initial market entry. For territories including the European Union, Brazil, and South Korea, the royalty percentage stands at 18% of net revenue. The payment obligation extends through May 2030.
The licensing arrangement provides comprehensive coverage for Yuviwel across every existing and prospective therapeutic application, encompassing achondroplasia, hypochondroplasia, and potential combination treatment protocols. This expansive framework ensures robust protection for BioMarin’s intellectual property far beyond the drug’s original approved indication.
The Trade-offs in the Settlement Agreement
As part of this resolution, BioMarin has committed to withdrawing its Section 337 complaint filed with the ITC. Additionally, ongoing legal proceedings in Brazil, Denmark, Germany, South Korea, and California’s Northern District will be dismissed.
Ascendis has further consented to refrain from contesting BioMarin’s patent validity and has accepted reciprocal regulatory non-interference provisions. This represents a substantial concession on Ascendis’s part.
The agreement serves as validation for BioMarin’s CNP therapeutic platform, which features its proprietary medication VOXZOGO (vosoritide) designed for pediatric patients diagnosed with achondroplasia. BioMarin dedicated considerable resources to advancing the foundational research, and this royalty arrangement represents tangible financial returns on that scientific commitment.
BioMarin’s Standing in Rare Disease Therapeutics
BioMarin CEO Alexander Hardy characterized this resolution as confirmation that sustained investment in rare disease research delivers meaningful results. The pharmaceutical company currently markets nine commercial products and has pioneered six first-in-category treatments for rare conditions.
The latest analyst assessment for BMRN assigns a Buy rating with an $88.00 price objective. The company commands a market capitalization approaching $12.52 billion.
Technical analysis indicators for BioMarin suggest a Buy position, with the stock price trading above significant moving averages and displaying positive MACD momentum. However, financial analysts have noted recent deterioration in profitability metrics and return on equity figures, alongside concerns about elevated P/E ratio valuations.
During its latest quarterly earnings presentation, the company upgraded its 2026 revenue projections, generating favorable investor sentiment as the fiscal year progresses.
This settlement establishes a supplementary royalty income stream linked to Yuviwel’s commercial performance across four strategic markets, contributing to BioMarin’s financial results through the end of the agreement in May 2030.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
